CN114732825A - Cardiac anti-stress product for livestock and poultry and preparation method thereof - Google Patents
Cardiac anti-stress product for livestock and poultry and preparation method thereof Download PDFInfo
- Publication number
- CN114732825A CN114732825A CN202210246254.6A CN202210246254A CN114732825A CN 114732825 A CN114732825 A CN 114732825A CN 202210246254 A CN202210246254 A CN 202210246254A CN 114732825 A CN114732825 A CN 114732825A
- Authority
- CN
- China
- Prior art keywords
- livestock
- poultry
- product
- heart
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000144972 livestock Species 0.000 title claims abstract description 47
- 244000144977 poultry Species 0.000 title claims abstract description 45
- 230000002180 anti-stress Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000747 cardiac effect Effects 0.000 title description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims abstract description 66
- 239000007787 solid Substances 0.000 claims abstract description 41
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 30
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 27
- 150000003943 catecholamines Chemical class 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 26
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract description 25
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract description 25
- 241000208011 Digitalis Species 0.000 claims abstract description 24
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims abstract description 22
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims abstract description 22
- 230000003177 cardiotonic effect Effects 0.000 claims abstract description 19
- 238000005728 strengthening Methods 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- 239000008103 glucose Substances 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- 210000004413 cardiac myocyte Anatomy 0.000 claims abstract description 13
- 230000036284 oxygen consumption Effects 0.000 claims abstract description 9
- 230000028161 membrane depolarization Effects 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 21
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 12
- 229940097217 cardiac glycoside Drugs 0.000 claims description 10
- 239000002368 cardiac glycoside Substances 0.000 claims description 10
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 10
- 229940111263 potassium magnesium aspartate Drugs 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- 229930002534 steroid glycoside Natural products 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 7
- 229960005156 digoxin Drugs 0.000 claims description 7
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 7
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 229960002105 amrinone Drugs 0.000 claims description 6
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 229960003638 dopamine Drugs 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229960003574 milrinone Drugs 0.000 claims description 6
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims description 6
- 229940068988 potassium aspartate Drugs 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 210000004165 myocardium Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 claims description 3
- NFFJLMKHRCXLJO-DKWTVANSSA-L magnesium;(2s)-2-aminobutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O NFFJLMKHRCXLJO-DKWTVANSSA-L 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 235000013594 poultry meat Nutrition 0.000 abstract description 32
- 206010049418 Sudden Cardiac Death Diseases 0.000 abstract description 2
- 230000022900 cardiac muscle contraction Effects 0.000 abstract description 2
- 235000013613 poultry product Nutrition 0.000 abstract description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003809 bile pigment Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000011128 cardiac conduction Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- LVBRFZFUCKKGDJ-HJWRJIQTSA-J magnesium;dipotassium;(2s)-2-aminobutanedioate;hydron Chemical compound [Mg+2].[K+].[K+].OC(=O)[C@@H](N)CC([O-])=O.OC(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O LVBRFZFUCKKGDJ-HJWRJIQTSA-J 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Fodder In General (AREA)
Abstract
The invention provides a heart strengthening and anti-stress product for livestock and poultry and a preparation method thereof, and relates to the technical field of livestock and poultry products, wherein the product specifically comprises the following raw materials by weight: 1000g of L-aspartic acid, 600g of potassium hydroxide solid, 600g of light magnesium oxide solid, 1-5g of catecholamine, 750g of glucose 250, 50-100g of digitalis medicine and 50-100g of phosphodiesterase inhibitor, and the components in the cardiotonic anti-stress product for livestock and poultry are mixed, so that after the cardiotonic anti-stress product is eaten by the livestock and poultry, the depolarization of cardiac muscle cells is promoted, the cardiac muscle contraction capability is maintained, the oxygen consumption is reduced, the cardiac muscle cell function is improved, and the heart is strengthened. The anti-stress product can protect the heart of livestock and poultry after being eaten, and prevent sudden cardiac death caused by stress reaction after the livestock and poultry are stimulated.
Description
Technical Field
The invention relates to the technical field of livestock and poultry products, in particular to a cardiotonic anti-stress product for livestock and poultry and a preparation method thereof.
Background
The anti-stress refers to the prevention of the stress behavior of animals, the stress is a series of neuroendocrine reactions mainly including sympathetic nerve excitation and pituitary-adrenal cortex secretion increase after the body is excessively stimulated by biological, physical and chemical factors existing in the external and internal environments, and various functional and metabolic changes caused by the neuroendocrine reactions, when the stress reaches a certain intensity or an individual has poor stress tolerance, the steady state of the body is damaged, and various pathophysiological reactions occur.
At present breed trade, to the breed in-process of beasts and birds, for letting beasts and birds can quick safe growth, generally all add a large amount of additives in the fodder of beasts and birds the inside for strengthen basic feed nutritive value, improve animal production performance, guarantee that the animal is healthy, save the fodder cost, improve aspects such as animal product quality, make the growth that beasts and birds can be quick, reduce the beasts and birds and grow required time, improve economic income.
However, the existing functional feed additives mainly promote the development of intestinal tracts and protect the digestive system, products for protecting the heart health of livestock and poultry are not researched, and because the livestock and poultry grow rapidly under the action of various functional additives, the development of the internal organs, particularly the development of the heart is relatively lagged relative to the development of body types, so that the heart load of the livestock and poultry is large in the process of rapid weight gain of the livestock and poultry, and the heart can cause the occurrence of the phenomenon of wall thickening under the condition that the heart is under high load for a long time, the condition of cardiac hypertrophy is caused, and the heart is enlarged over time along with the development of time, so that the wall is thinned, and the symptoms of heart failure are caused.
Meanwhile, in the process of breeding livestock and poultry, the livestock and poultry are easily influenced by the breeding environment to generate stress response, and the steady state of the heart rhythm is also greatly impacted at the moment, so that the incidence rate of arrhythmia is obviously increased, and malignant arrhythmia and sudden cardiac death occur.
Disclosure of Invention
The invention aims to solve the defects in the background technology and provides a cardiotonic anti-stress product for livestock and poultry and a preparation method thereof.
In order to achieve the purpose, the invention provides the following technical scheme, and the heart strengthening anti-stress product for livestock and poultry and the preparation method thereof are characterized in that the product specifically comprises the following raw materials by weight: 1000g of L-aspartic acid, 600g of potassium hydroxide solid, 600g of light magnesium oxide solid, 1-5g of catecholamine, 750g of glucose 250, 50-100g of digitalis medicine and 50-100g of phosphodiesterase inhibitor, and the components in the cardiotonic anti-stress product for livestock and poultry are prepared, so that after the cardiotonic anti-stress product is eaten by the livestock and poultry, the depolarization of cardiac muscle cells is promoted, the contractility of cardiac muscle is maintained, the oxygen consumption is reduced, the function of the cardiac muscle cells is improved, and the heart is strengthened.
Further, the catecholamine comprises at least dopamine, and the dopamine content is at least 80mg/10 g.
Further, the phosphodiesterase inhibitor at least comprises milrinone and amrinone, wherein the milrinone content is at least 10mg/100g, and the amrinone content is at least 5mg/100 g.
Further, the digitalis medicine comprises digoxin, cardiac glycoside and cydiolan, wherein the content of the digoxin is at least 50g/100g, the content of the cardiac glycoside is at least 40g/100g, and the content of the cydiolan is at least 1g/10 g.
Further, the optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 500g of L-aspartic acid, 300g of potassium hydroxide solid, 300g of light magnesium oxide solid, 1g of catecholamine, 250g of glucose, 50g of digitalis medicine and 50g of phosphodiesterase inhibitor.
Further, the optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 1000g of L-aspartic acid, 500g of potassium hydroxide solid, 600g of light magnesium oxide solid, 3g of catecholamine, 500g of glucose, 60g of digitalis medicine and 70g of phosphodiesterase inhibitor.
Further, the optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 750g of L-aspartic acid, 400g of potassium hydroxide solid, 400g of light magnesium oxide solid, 2g of catecholamine, 500g of glucose, 80g of digitalis medicine and 70g of phosphodiesterase inhibitor.
Further, the optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 777.5g of L-aspartic acid, 358.7g of potassium hydroxide solid, 165.8g of light magnesium oxide solid, 1g of catecholamine, 250g of glucose, 60g of digitalis medicine and 60g of phosphodiesterase inhibitor.
Further, a preparation method of the heart strengthening anti-stress product for livestock and poultry comprises the following steps:
s1, adding 777.5g of L-aspartic acid and 1.5L of purified water into a reaction vessel, fully and uniformly stirring until the L-aspartic acid and the purified water are completely dissolved, and then slowly adding 358.7g of potassium hydroxide solid while stirring;
s2, reacting the potassium hydroxide solid with L-aspartic acid and purified water to generate a large amount of heat, cooling to room temperature (20-25 ℃) and then continuously stirring until the system is dissolved clearly;
s3, detecting the pH value of the solution to be 7.5-8.0 at room temperature;
s4, finely filtering the solution through a filter membrane with the aperture of 0.45 mu m to obtain 3L of L-potassium aspartate solution;
s5, adding 922.6 gL-aspartic acid and 2L purified water into a reaction vessel, heating to the internal temperature of 40 ℃, and fully and uniformly stirring until the materials are completely dissolved;
s6, slowly adding 165.8g of light magnesium oxide solid while stirring under the condition of heat preservation, at the moment, releasing heat in the reaction, and continuously stirring until the system is clear;
s7, cooling to room temperature (20-25 ℃), detecting the pH value of the solution to be 7.5-8.0, and then performing fine filtration through a filter membrane with the pore diameter of 0.45 mu m to obtain 3.3L of L-aspartic acid magnesium salt solution;
s8, adding the L-potassium aspartate solution and the L-magnesium aspartate solution into a reaction container, fully and uniformly stirring to obtain an L-potassium magnesium aspartate solution, and detecting the pH value of a system at room temperature (20-25 ℃) to be 7.0-8.0;
s9, then forming fog drops by the L-potassium magnesium aspartate solution through an atomizer, spraying the fog drops into a drying chamber for spray drying, wherein the flow direction of drying air is the same as the spraying direction of the solution, the air inlet temperature is 130-200 ℃, the air outlet temperature is 40-120 ℃, and about 1.8kg of L-potassium magnesium aspartate salt product is obtained;
s10, mixing catecholamine, glucose, digitalis medicaments, a phosphodiesterase inhibitor and an L-potassium magnesium aspartate product according to a weight ratio, and filling the mixture into a sterile carrier for storage.
The invention provides a heart strengthening anti-stress product for livestock and poultry and a preparation method thereof, and the product has the following beneficial effects:
1. the invention has the advantages that the normal excitability and the stability of the internal environment of the cell are maintained through the strong affinity of the aspartic acid and the cell, the depolarization of the cardiac muscle cell is promoted, the cardiac muscle contraction capability is maintained, and the oxygen consumption is reduced, thereby improving the function of the cardiac muscle cell and strengthening the heart.
2. And secondly, the production of urea can be promoted through aspartic acid, the content of ammonia nitrogen and CO2 in blood is reduced, the excretion of bile and bile pigment can be promoted, and the effects of yellow discharge, liver fat reduction, liver glycogen increase and liver protection are achieved.
3. Subsequently, catecholamine and digitalis drugs can enhance the action of myocardial contractility, increase the cardiac output without increasing the myocardial oxygen consumption, and simultaneously play a role in regulating the extracellular fluid volume and composition and the metabolism of water and electrolytes.
Drawings
FIG. 1 is a flow chart of the preparation of the present invention.
Detailed Description
The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application. It is to be understood that the embodiments described are only a few embodiments of the present application and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
In the description of the present application, it is to be understood that the terms "center," "longitudinal," "lateral," "length," "width," "thickness," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," "clockwise," "counterclockwise," and the like are used in the orientations and positional relationships indicated in the drawings for convenience in describing the present application and for simplicity in description, and are not intended to indicate or imply that the referenced devices or elements must have a particular orientation, be constructed in a particular orientation, and be operated in a particular manner, and are not to be construed as limiting the present application. Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, features defined as "first", "second", may explicitly or implicitly include one or more of the described features. In the description of the present application, "a plurality" means two or more unless specifically limited otherwise.
In the description of the present application, it should be noted that, unless otherwise explicitly stated or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, and may be, for example, a fixed connection, a detachable connection, or an integral connection; may be mechanically connected, may be electrically connected or may be in communication with each other; either directly or indirectly through intervening media, either internally or in any other relationship. The specific meaning of the above terms in the present application can be understood by those of ordinary skill in the art as the case may be.
In this application, unless expressly stated or limited otherwise, the first feature "on" or "under" the second feature may comprise direct contact of the first and second features, or may comprise contact of the first and second features not directly but through another feature in between. Also, the first feature being "on," "above" and "over" the second feature includes the first feature being directly on and obliquely above the second feature, or merely indicating that the first feature is at a higher level than the second feature. "beneath," "under" and "beneath" a first feature includes the first feature being directly beneath and obliquely beneath the second feature, or simply indicating that the first feature is at a lesser elevation than the second feature.
The following disclosure provides many different embodiments or examples for implementing different features of the application. In order to simplify the disclosure of the present application, specific example components and arrangements are described below. Of course, they are merely examples and are not intended to limit the present application. Moreover, the present application may repeat reference numerals and/or letters in the various examples, such repetition is for the purpose of simplicity and clarity and does not in itself dictate a relationship between the various embodiments and/or configurations discussed. In addition, examples of various specific processes and materials are provided herein, but one of ordinary skill in the art may recognize applications of other processes and/or use of other materials.
Example 1:
the product for strengthening heart and resisting stress for livestock and poultry and the preparation method thereof provided by the embodiment specifically comprises the following raw materials by weight: 1000g of L-aspartic acid, 600g of potassium hydroxide solid, 600g of light magnesium oxide solid, 1-5g of catecholamine, 750g of glucose 250, 50-100g of digitalis medicine and 50-100g of phosphodiesterase inhibitor, and the components in the cardiotonic anti-stress product for livestock and poultry are prepared, so that after the cardiotonic anti-stress product is eaten by the livestock and poultry, the depolarization of cardiac muscle cells is promoted, the contractility of cardiac muscle is maintained, the oxygen consumption is reduced, the function of the cardiac muscle cells is improved, and the heart is strengthened.
Further, said catecholamines comprise at least dopamine, and said dopamine content is at least 80mg/10g, having an effect on the cardiovascular system: catecholamines act on the heart through beta-1 receptors, so that the heart rate is accelerated, the contractility is enhanced, the conduction speed is increased, the cardiac output is increased, the catecholamines participate in the regulation of thermogenesis, and the oxygen consumption is increased through the beta receptors to generate heat. And can promote the decomposition of energy-storing substances in the organism, and the catecholamine has important regulation effect on the capacity and the composition of extracellular fluid and the metabolism of water and electrolyte.
Further, the phosphodiesterase inhibitor at least comprises milrinone and amrinone, the milrinone content is at least 10mg/100g, the amrinone content is at least 5mg/100g, and myocardial contractility can be enhanced by inhibiting phosphodiesterase activity to promote calcium ion channel membrane protein phosphorylation and calcium ion influx increase.
Further, the digitalis medicine comprises digoxin, cardiac glycoside and cydiolan, the content of the digoxin is at least 50g/100g, the content of the cardiac glycoside is at least 40g/100g, the content of the cydiolan is at least 1g/10g, the digitalis medicine has the effects of increasing myocardial contractility and slowing down heart rate and can increase the blood discharge amount of the heart without increasing the oxygen consumption of the heart muscle, the digoxin is an intermediate-effect cardiac glycoside medicine and is white crystalline powder, the effect on the heart is positive inotropic effect, the heart rate is slowed down and the cardiac conduction is inhibited, the cardiac glycoside is a medicine for increasing the myocardial contractility and is also called cardiac glycoside or cardiac glycoside, the cydiolan is a quick cardiotonic and can enhance the myocardial contraction and slow down the heart rate and the cardiac conduction, but the effect is quick and the accumulation is small.
Furthermore, the L-aspartic acid has strong affinity with cells, can be used as a carrier to enable K + and Mg2+ to rapidly enter cells and mitochondria, maintain the normal excitability and the stability of the internal environment of the cells, can also target and load K + and Mg2+ to enrich cardiac muscle cells, promote the depolarization of the cardiac muscle cells, maintain the myocardial contractility, reduce the oxygen consumption, thereby improving the functions of the cardiac muscle cells and strengthening the heart.
Furthermore, the L-aspartic acid can also promote urea generation, reduce the content of ammonia nitrogen and CO2 in blood, promote the excretion of bile and bile pigment, discharge yellow, reduce liver fat, increase liver glycogen and protect liver.
Example 2
The optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 500g of L-aspartic acid, 300g of potassium hydroxide solid, 300g of light magnesium oxide solid, 1g of catecholamine, 50g of digitalis medicine and 50g of phosphodiesterase inhibitor.
Example 3
The optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 1000g of L-aspartic acid, 500g of potassium hydroxide solid, 600g of light magnesium oxide solid, 3g of catecholamine, 500g of glucose, 60g of digitalis medicine and 70g of phosphodiesterase inhibitor.
Example 4
The optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 750g of L-aspartic acid, 400g of potassium hydroxide solid, 400g of light magnesium oxide solid, 2g of catecholamine, 500g of glucose, 80g of digitalis medicine and 70g of phosphodiesterase inhibitor.
Example 5
The optimal proportion of the cardiotonic anti-stress product for livestock and poultry is as follows: 777.5g of L-aspartic acid, 358.7g of potassium hydroxide solid, 165.8g of light magnesium oxide solid, 1g of catecholamine, 250g of glucose, 60g of digitalis medicine and 60g of phosphodiesterase inhibitor.
Example 6
The broiler chicken grows fast, the metabolism is vigorous, myocardial hypertrophy or weakness often occurs on the site, the heart is well maintained, the blood and oxygen supply and oxygen delivery capacity is enhanced, the anti-stress level is improved, and the experiment researches the influence of different feed additives on the production performance of heat-stress broiler chickens.
Test products: the magnesium is a product mainly comprising potassium magnesium aspartate, and 1kg of magnesium is added into each ton of water;
from 1 day of age to slaughter. The control group is a blank experiment.
Test chicken: one day old AA broilers, housed in cages, were divided into 6 groups of approximately 1800 chickens each.
Feeding management: the food and water can be taken freely. And (4) carrying out conventional immunization. The test period ranged from 6 months 1 to 7 months 13.
The invention relates to a preparation method of a heart strengthening anti-stress product for livestock and poultry, which comprises the following steps:
s1, adding 777.5g of L-aspartic acid and 1.5L of purified water into a reaction vessel, fully and uniformly stirring until the materials are completely dissolved, and then slowly adding 358.7g of potassium hydroxide solid while stirring;
s2, reacting the potassium hydroxide solid with L-aspartic acid and purified water to generate a large amount of heat, cooling to room temperature (20-25 ℃) and then continuously stirring until the system is dissolved clearly;
s3, detecting the pH value of the solution to be 7.5-8.0 at room temperature;
s4, finely filtering the solution through a filter membrane with the aperture of 0.45 mu m to obtain 3L of L-potassium aspartate solution;
s5, adding 922.6 gL-aspartic acid and 2L purified water into a reaction vessel, heating to the internal temperature of 40 ℃, and fully and uniformly stirring until the materials are completely dissolved;
s6, slowly adding 165.8g of light magnesium oxide solid while stirring under the condition of heat preservation, at the moment, releasing heat in the reaction, and continuously stirring until the system is clear;
s7, cooling to room temperature (20-25 ℃), detecting the pH value of the solution to be 7.5-8.0, and then performing fine filtration through a filter membrane with the pore diameter of 0.45 mu m to obtain 3.3L of L-aspartic acid magnesium salt solution;
s8, adding the L-potassium aspartate solution and the L-magnesium aspartate solution into a reaction container, fully and uniformly stirring to obtain an L-potassium magnesium aspartate solution, and detecting the pH value of a system at room temperature (20-25 ℃) to be 7.0-8.0;
s9, then forming fog drops by the L-potassium magnesium aspartate solution through an atomizer, spraying the fog drops into a drying chamber for spray drying, wherein the flow direction of drying air is the same as the spraying direction of the solution, the air inlet temperature is 130-200 ℃, the air outlet temperature is 40-120 ℃, and about 1.8kg of L-potassium magnesium aspartate salt product is obtained;
s10, mixing catecholamine, digitalis medicaments, a phosphodiesterase inhibitor and the L-potassium magnesium aspartate product according to the weight ratio, and filling into a sterile packaging bag.
In the foregoing embodiments, the descriptions of the respective embodiments have respective emphasis, and for parts that are not described in detail in a certain embodiment, reference may be made to related descriptions of other embodiments.
The foregoing describes in detail a cardiac anti-stress product for livestock and poultry and a preparation method thereof provided in the embodiments of the present application, and the principles and embodiments of the present application are explained in the present application by applying specific examples, and the description of the foregoing embodiments is only used to help understanding the technical solutions and core ideas of the present application; those of ordinary skill in the art will understand that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; such modifications or substitutions do not depart from the spirit and scope of the present disclosure as defined by the appended claims.
Claims (9)
1. A heart strengthening and stress resisting product for livestock and poultry and a preparation method thereof are characterized in that the product specifically comprises the following raw materials by weight: 1000g of L-aspartic acid, 600g of potassium hydroxide solid, 600g of light magnesium oxide solid, 1-5g of catecholamine, 750g of glucose 250, 50-100g of digitalis medicine and 50-100g of phosphodiesterase inhibitor, and the components in the cardiotonic anti-stress product for livestock and poultry are prepared, so that after the cardiotonic anti-stress product is eaten by the livestock and poultry, the depolarization of cardiac muscle cells is promoted, the contractility of cardiac muscle is maintained, the oxygen consumption is reduced, the function of the cardiac muscle cells is improved, and the heart is strengthened.
2. The product of claim 1, wherein the catecholamine comprises at least dopamine, and the dopamine content is at least 80mg/10 g.
3. The product of claim 1, wherein the phosphodiesterase inhibitor comprises milrinone and amrinone, the milrinone content is at least 10mg/100g, and the amrinone content is at least 5mg/100 g.
4. The product of claim 1, wherein the digitalis drug comprises digoxin, cardiac glycoside and cydiolan, the digoxin is at least 50g/100g, the cardiac glycoside is at least 40g/100g, and the cydiolan is at least 1g/10 g.
5. The livestock and poultry heart-strengthening anti-stress product and the preparation method thereof as claimed in claim 1, characterized in that the optimal mixture ratio of the livestock and poultry heart-strengthening anti-stress product is as follows: 500g of L-aspartic acid, 300g of potassium hydroxide solid, 300g of light magnesium oxide solid, 1g of catecholamine, 250g of glucose, 50g of digitalis medicine and 50g of phosphodiesterase inhibitor.
6. The livestock and poultry heart-strengthening anti-stress product and the preparation method thereof according to claim 1, characterized in that the optimal mixture ratio of the livestock and poultry heart-strengthening anti-stress product is as follows: 1000g of L-aspartic acid, 500g of potassium hydroxide solid, 600g of light magnesium oxide solid, 3g of catecholamine, 500g of glucose, 60g of digitalis medicine and 70g of phosphodiesterase inhibitor.
7. The livestock and poultry heart-strengthening anti-stress product and the preparation method thereof according to claim 1, characterized in that the optimal mixture ratio of the livestock and poultry heart-strengthening anti-stress product is as follows: 750g of L-aspartic acid, 400g of potassium hydroxide solid, 400g of light magnesium oxide solid, 2g of catecholamine, 500g of glucose, 80g of digitalis medicine and 70g of phosphodiesterase inhibitor.
8. The livestock and poultry heart-strengthening anti-stress product and the preparation method thereof according to claim 1, characterized in that the optimal mixture ratio of the livestock and poultry heart-strengthening anti-stress product is as follows: 777.5g of L-aspartic acid, 358.7g of potassium hydroxide solid, 165.8g of light magnesium oxide solid, 1g of catecholamine, 250g of glucose, 60g of digitalis medicine and 60g of phosphodiesterase inhibitor.
9. A method for preparing a heart-strengthening anti-stress product for livestock and poultry comprises the following steps:
s1, adding 777.5g of L-aspartic acid and 1.5L of purified water into a reaction vessel, fully and uniformly stirring until the materials are completely dissolved, and then slowly adding 358.7g of potassium hydroxide solid while stirring;
s2, reacting the potassium hydroxide solid with L-aspartic acid and purified water to generate a large amount of heat, cooling to room temperature (20-25 ℃), and then continuously stirring until the system is dissolved;
s3, detecting the pH value of the solution to be 7.5-8.0 at room temperature;
s4, finely filtering the solution through a filter membrane with the aperture of 0.45 mu m to obtain 3L of L-potassium aspartate solution;
s5, adding 922.6 gL-aspartic acid and 2L purified water into a reaction vessel, heating to the internal temperature of 40 ℃, and fully and uniformly stirring until the materials are completely dissolved;
s6, slowly adding 165.8g of light magnesium oxide solid while stirring under the condition of heat preservation, at the moment, releasing heat in the reaction, and continuously stirring until the system is clear;
s7, cooling to room temperature (20-25 ℃), detecting the pH value of the solution to be 7.5-8.0, and then performing fine filtration through a filter membrane with the pore diameter of 0.45 mu m to obtain 3.3L of L-aspartic acid magnesium salt solution;
s8, adding the L-potassium aspartate solution and the L-magnesium aspartate solution into a reaction container, fully and uniformly stirring to obtain an L-potassium magnesium aspartate solution, and detecting the pH value of a system at room temperature (20-25 ℃) to be 7.0-8.0;
s9, then forming fog drops by the L-potassium magnesium aspartate solution through an atomizer, spraying the fog drops into a drying chamber for spray drying, wherein the flow direction of drying air is the same as the spraying direction of the solution, the air inlet temperature is 130-200 ℃, the air outlet temperature is 40-120 ℃, and about 1.8kg of L-potassium magnesium aspartate salt product is obtained;
s10, mixing catecholamine, glucose, digitalis drugs, a phosphodiesterase inhibitor and an L-potassium magnesium aspartate product according to the weight ratio, and filling the mixture into a sterile carrier for storage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210246254.6A CN114732825A (en) | 2022-03-14 | 2022-03-14 | Cardiac anti-stress product for livestock and poultry and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210246254.6A CN114732825A (en) | 2022-03-14 | 2022-03-14 | Cardiac anti-stress product for livestock and poultry and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114732825A true CN114732825A (en) | 2022-07-12 |
Family
ID=82275775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210246254.6A Pending CN114732825A (en) | 2022-03-14 | 2022-03-14 | Cardiac anti-stress product for livestock and poultry and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114732825A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1351866A (en) * | 2001-11-22 | 2002-06-05 | 于航 | Levo-potassium magnesium aspartate freeze drying powder injection and preparing method |
| CN1830431A (en) * | 2005-03-08 | 2006-09-13 | 巴里莫尔制药（通化）有限公司 | Preparation method of potassium magnesium aspartate freeze dried powder injection |
| CN101301311A (en) * | 2007-05-10 | 2008-11-12 | 深圳北大高科五洲医药有限公司 | Potassium magnessium aspartape sterilized powder injection and preparation thereof |
| KR20170115293A (en) * | 2016-04-07 | 2017-10-17 | 대한뉴팜(주) | Feed additive for relaxing stress of livestock and method for relaxing stress of livestock using the same |
| CN110731967A (en) * | 2019-12-03 | 2020-01-31 | 海南顿斯医药科技有限公司 | potassium magnesium aspartate composition and application thereof |
| CN113209032A (en) * | 2021-05-26 | 2021-08-06 | 海南通用康力制药有限公司 | Potassium magnesium aspartate freeze-dried powder injection for injection and preparation method thereof |
-
2022
- 2022-03-14 CN CN202210246254.6A patent/CN114732825A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1351866A (en) * | 2001-11-22 | 2002-06-05 | 于航 | Levo-potassium magnesium aspartate freeze drying powder injection and preparing method |
| CN1830431A (en) * | 2005-03-08 | 2006-09-13 | 巴里莫尔制药（通化）有限公司 | Preparation method of potassium magnesium aspartate freeze dried powder injection |
| CN101301311A (en) * | 2007-05-10 | 2008-11-12 | 深圳北大高科五洲医药有限公司 | Potassium magnessium aspartape sterilized powder injection and preparation thereof |
| KR20170115293A (en) * | 2016-04-07 | 2017-10-17 | 대한뉴팜(주) | Feed additive for relaxing stress of livestock and method for relaxing stress of livestock using the same |
| CN110731967A (en) * | 2019-12-03 | 2020-01-31 | 海南顿斯医药科技有限公司 | potassium magnesium aspartate composition and application thereof |
| CN113209032A (en) * | 2021-05-26 | 2021-08-06 | 海南通用康力制药有限公司 | Potassium magnesium aspartate freeze-dried powder injection for injection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 吉增福，赵永军，张学富，苏金平: "家畜心力衰竭的治疗", 中国兽医科技, vol. 2006, no. 05, pages 410 - 413 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102550836B (en) | Animal nutrition additive trace element is combined bag and its preparation method and application | |
| WO2022063295A1 (en) | Additive for increasing survival rate of aquaculture animals and application thereof | |
| US11864568B2 (en) | Polyhalite enriched animal feed | |
| CN111072508B (en) | Preparation method and application of zinc valine | |
| CN110692821B (en) | Feed additive for improving rumen fermentation efficiency of cattle | |
| CN101786961A (en) | Chromium threonine, preparation method and application thereof | |
| CN114732825A (en) | Cardiac anti-stress product for livestock and poultry and preparation method thereof | |
| CN106243176B (en) | The copper complex formazan preparation method of sucrose | |
| CN102578386B (en) | Compound many ore deposits of glycine and its preparation method and application | |
| CN102422985B (en) | Iodine, selenium and cobalt composite package for animal feed and preparation method and application method thereof | |
| CN102550830B (en) | Method for applying and preparing gamma-aminobutyric acid complex compound | |
| CN101669911B (en) | Dicazuril soluble powder and preparation method thereof | |
| CN101559074A (en) | Coccidiostat-decoquinate dry suspension for livestock and poultry and preparation method thereof | |
| CN112409200B (en) | Preparation method and application of isoleucine chelate metal | |
| CN109123101A (en) | The application of a kind of preparation method and niacin manganese of niacin manganese in animal feed | |
| CN104208657B (en) | A kind of virginiamycin soluble powder and preparation method thereof | |
| CN102007884A (en) | Method for producing eggs rich in multiple trace elements | |
| CN101601439A (en) | Contain butyrate mixture and the method for making and the application in feed addictive of potassium butyrate | |
| CN113100351A (en) | Feed additive, application thereof and compound feed for relieving ovarian senescence of laying hens | |
| CN105851622A (en) | Microelement premix for improving eggshell strength and preparing method thereof | |
| CN1969863A (en) | Vitamin composition used for marine product | |
| RU2792895C1 (en) | Feed additive based on the mineral kaolinite to increase the resistance and productivity of rabbits | |
| CN111116394B (en) | Preparation method and application of ferrous valine | |
| JPH03284621A (en) | Solid composition | |
| CN110897039B (en) | Preparation method and application of manganese valine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220712 |